Genentech
is recruiting U.S. participants for a Phase 3 study (NCT02637856) of Ocrevus
(ocrelizumab) in people with relapsing-remitting multiple sclerosis (RRMS) who
were not helped by previous disease-modifying therapies, according to a
press release from the National Multiple Sclerosis Society. The trial is an
open-label study, meaning that all participants will receive Ocrevus
For RRMS patients, there are two open and recruiting Phase 3B clinical trials.
See links below for more details.
OBOE:
CHORDS:
===================================================
MS Views and News
Providing educational information, resources and services for those affected by MS
Click here to receive MS news via e-mail
““““““““““““““““““““““““““““`
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews